Products pipeline

The research pipeline is extensive with projects at different stages of maturity.

The research pipeline is extensive with projects at different stages of maturity, ranging from allogeneic cardiopoietic stem cells for the treatment on acute myocardial infarction to, various substances to promote the heart self regenerative capacity, agents to increase cell retention using tissue engineering capabilities, the use of various sources of mesenchymal stem cells and Induced Pluripotent Stem Cells.Cardio3 BioSciences is also in late stages for the development of a specific delivery system that will increase cell retention and facilitate accurate injections.

Graphs and timeline

C-Cure®

C-Cure®, Cardio3 BioSciences’ lead product, is a second-generation cell therapy for the treatment of heart failure  Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

C-Cure is  based on the concept of committing adult stem cells toward the cardiac lineage in vitro prior to transplantation. The technology of the commitment of adult stem cells to the cardiac lineage relies on fundamental research conducted at the Mayo Clinic, Rochester, MN, USA. Using an in vitro assay mimicking cardiogenesis, Mayo Clinic physicians combined genomic and proteomic approaches to dissect critical cardiotrophic factors leading to the formulation of a cardiogenic cocktail. When used on human bone marrow-derived mesenchymal stem cells, this cardiogenic cocktail allowed derivation of a homogeneous population of cardiopoietic cells. In vivo assays demonstrated the superior effect of cardiopoietic cells on functional improvement and de novo heart muscle repair, compared to naïve human bone marrow-derived mesenchymal stem cells.

Treated condition - Chronic Heart Failure

Chronic Heart Failure (CHF) is a debilitating serious condition in which the heart is unable to pump enough blood to meet the body metabolic needs. Patients suffering from heart failure experience shortness of breath, extreme exhaustion, and accumulation of liquid in the body. Chronic Heart Failure can be caused by heart attacks (ischemic origin) or by numerous other causes such as severe hypertension, valvular diseases, diabetes, metabolic or toxic diseases. All available therapies for chronic heart failure aim at slowing down the disease progression, but with the exception of heart transplant, existing drugs or devices do not cure Chronic Heart Failure.  More information on the disease is available on the “Study Group on Heart Failure Awareness and Perception in Europe” (SHAPE) and on the “Heart Failure Online” web sites.

C-Cure²:

Autologous therapy using Mesenchymal Stem Cells originating from the adipose tissue and programmed to a cardiopoietic stage.

C-Cure² has the potential to increase the potency of C-Cure and to facilitate the manufacturing process by an increase cell yield and a faster doubling time.


Allo-Cure:

Allogeneic cardiopoietic cells injected primarily in acute or sub-acute myocardial infarction setting, serving as reservoir of growth factors to activate and differentiate cardiac resident stem cells in order to reduce severity of the initial injury, and promote tissue regeneration.


G-Cure

• G-Cure 1: A cocktail of growth factors (proteins) injected in the acute phase of an infarct to reduce the apoptosis and necrosis, and stimulate resident cardiac stem cells to limit infarct size.
• G-Cure 2: A different cocktail of growth factors issued from the analysis of the secretome of potent stem cells.

C-Cath:

A intramyocardial injection catheter to alow accurate and safe delivery of therapeutic agents in an organ, with superior retention capacity.